|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Department of Dermatology, University of
Mainz, Germany.
Interleukin-10 (IL-10)-treated dendritic cells (DCs) induce an
alloantigen- or peptide-specific anergy in various CD4+ and
CD8+ T-cell populations. In the present study, we analyzed
whether these anergic T cells are able to regulate antigen-specific
immunity. Coculture experiments revealed that alloantigen-specific
anergic CD4+ and CD8+ T cells suppressed
proliferation of syngeneic T cells in a dose-dependent manner. The same
effect was observed when the hemagglutinin-specific CD4+
T-cell clone HA1.7 or tyrosinase-specific CD8+ T cells were
cocultured with anergic T cells of the same specificity. Anergic T
cells did not induce an antigen-independent bystander inhibition.
Suppression was dependent on cell-to-cell contact between anergic and
responder T cells, required activation by antigen-loaded DCs, and was
not mediated by supernatants of anergic T cells. Furthermore, anergic T
cells displayed an increased extracellular and intracellular expression
of cytotoxic T-lymphocye antigen (CTLA)-4 molecules, and
blocking of the CTLA-4 pathway restored the T-cell proliferation up to
70%, indicating an important role of the CTLA-4 molecule in the
suppressor activity of anergic T cells. Taken together, our experiments
demonstrate that anergic T cells induced by IL-10-treated DCs are able
to suppress activation and function of T cells in an antigen-specific
manner. Induction of anergic T cells might be exploited therapeutically
for suppression of cellular immune responses in allergic or autoimmune
diseases with identified (auto) antigens.
(Blood. 2002;99:2468-2476) The task of eliminating autoreactive T cells is
mediated in part by clonal deletion in the thymus. Autoreactive T cells
that did not undergo negative selection in the thymus are subject to several peripheral mechanisms controlling unwanted T-cell
activation.1 These include immunological ignorance,
deletion, immunoregulation, and anergy.2-5 Maintenance of
tolerance might be of clinical importance not only for self-tolerance
but also for the control of pathogen-induced immune
processes.6,7
Anergy is immunologically defined as the inability of antigen-specific
T cells to produce interleukin (IL)-2 and to clonally expand on
rechallenge with fully competent antigen-presenting cells
(APCs).8 Induction of anergy is an active process that occurs when T-cell receptors (TCRs) are ligated by antigen in the
absence of costimulation.9 Anergy can also be induced in the presence of costimulation when the TCR is ligated by superantigen or by altered peptide ligands that bear a single amino acid
substitution in the sequence of the agonistic
peptide.10,11 Although quite distinct, these approaches to
induce anergy appear to share common biochemical events characterized
by hypophosphorylation of several signal transduction-related
proteins.12-15 One important aspect of this type of
regulation is that alloreactive T cells, tolerant to a specific antigen
(alloantigen/autoantigen), can potentially down-regulate the response
of other naive allogeneic or antigen-specific T
cells.16,17
Dendritic cells (DCs) are highly specialized APCs of the immune
system.18 Fully mature DCs are potent activators of naive T cells and are regarded as important initiators of primary T-cell immune responses. In contrast to modulators inducing the maturation of
DCs, the immunosuppressive properties of IL-10 on DCs have been well
documented in several studies.19 The inhibitory influence of IL-10 on APC function of DCs may be due to several phenotypic and
functional alterations, such as down-regulation of major
histocompatibility complex class II and costimulatory molecules
and the reduced secretion of a variety of inflammatory
cytokines.20-23 Additionally, it was shown that
IL-10-treated LCs (Langerhans cells) induce an
antigen-specific tolerance in TH1, but not in
TH2 cell clones.24 Recently, we showed that
IL-10-treated human DCs generated from peripheral blood induce a state
of antigen-specific anergy in CD4+ and CD8+ T
cells.25,26 These anergic T cells are characterized by an impaired proliferative capacity, reduced production of IL-2 and interferon (IFN)- In the present study, we analyzed the effect of anergic T cells induced
by IL-10-treated DCs on naive syngeneic T cells or activated
antigen-specific CD4+ and CD8+ T-cell lines and
clones. We will demonstrate that anergic T cells suppress proliferation
of cocultured T cells of the same alloantigen or peptide specificity,
but induce no bystander suppression. This suppression is mediated in
part by stimulation of the cytotoxic T-lymphocye antigen (CTLA)-4
molecule on anergic T cells, is dependent on cell-to-cell contact
between the cocultured T cells, and is independent of soluble mediators produced.
Culture medium
Cytokines
Antibodies For immunostaining, mouse immunoglobulin (Ig)-G, the following were used: CD2, CD3, CD4, CD8, CD11a, CD25, CD28, CD40L, CD58, CD62L, CD69, CD122 (Pharmingen, Hamburg, Germany), CTLA-4 (Alexis Biochemicals, San Diego, CA), mouse subclass-specific isotypes (Coulter/Immunotech, Fullerton, CA). Conjugated secondary reagents were as follows: fluorescein isothiocyanate (FITC)-conjugated goat-antimouse IgG (Jackson Immunoresearch, West Grove, PA). Staining of magnetic activated cell sorting (MACS)-sorted T cells: FITC- or phycoerythrin (PE)-conjugated CD4 or CD8; FITC- and PE-conjugated mouse IgG (Coulter/Immunotech).Flow cytometric analysis Immunofluorescence staining was performed after washing the cells twice with phosphate-buffered saline (PBS) plus 0.5% human serum albumin (HSA). Cells were incubated for 20 minutes at 4°C with each monoclonal antibody (mAb) diluted to the optimal concentration for immunostaining. After washing with cold PBS/HSA, the cells were incubated with FITC- and PE-conjugated second-step mAb for 20 minutes at 4°C, washed 3 times, and analyzed by flow cytometry (FACScalibur, Cellquest software) (Becton Dickinson, Mountain View, CA).For intracellullar analysis of CTLA-4 expression, 48 hours after restimulation T cells were collected, washed, fixed/saponin-permeabilized (perm/fix-solution, Pharmingen), and stained with 0.5 µg CTLA-4-specific or IgG control antibodies per test. Generation of DCs DCs were generated from buffy coats or leukapheresis products as described before.27 Briefly, peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation and used immediately or stored frozen in aliquots. For each DC preparation, monocytes were isolated by plastic adherence and cultured in X-VIVO-15 plus 1% heat-inactivated autologous plasma including 800 U/mL GM-CSF and 1000 U/mL IL-4. At day 7, nonadherent cells were rinsed off, washed once in PBS, and transferred to 6-well plates at 7 × 105 cells in 3 mL per well. For differentiation into mature DCs, immature DCs were additionally stimulated on day 7 with 10 ng/mL IL-1 , 10 ng/mL TNF- 1000 U/mL IL-6, and 1 µg/mL PGE2. For the generation of anergy-inducing DCs, IL-10 (40 ng/mL) was added to the
DCs at day 7 after stimulation with the cytokines. Nonadherent DCs at
day 9 were used for T-cell stimulation.
Induction of alloreactive T cells and proliferation assays Naive CD4+/CD8+ T cells were purified with MACS-Beads as indicated by the manufacturer (Miltenyi, Bergisch-Gladbach, Germany) (purity: greater than 98% CD4+/CD8+, greater than 90% CD45RA+). Subsequently, 106 T cells were cultured with 105 mature DCs or IL-10-treated DCs in 1 mL X-VIVO-20 in 24-well plates to generate anergic or optimally stimulated control T cells. These T cells were used in anergy assays or coculture experiments and are referred to here as anergic T cells or activated control T cells (CTs). Parts of the cultures were used for proliferation assays carried out in X-VIVO-20 with 1 × 105 T cells per well and different numbers of allogeneic DCs in 96-well plates. T-cell proliferation was measured after 3 days of incubation, and an additional 16-hour pulse with 3H-Tdr (37 kBq per well) by means of a liquid scintillation counter.Tyrosinase-specific and melanoma antigen recognized by T cells-specific CD8+ T-cell lines and tetanus-toxoid-specific CD4+ T-cell lines CD8+ T cells (2 × 105) from HLA-A2+ donors (purity greater than 95% CD8+ T cells, generated as described above) were cultured in X-VIVO 20 and stimulated with mature, HLA-A2+, autologous DCs (2 × 104) pulsed with the specific tyrosinase peptide (Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val) or melanoma antigen recognized by T cells (MART-1) peptide (Glu-Ala-Ala-Gly-Ile-Gly-Leu-Thr-Val) (20 µg/mL). For the generation of tetanus-toxoid (TT)-specific T-cell lines, T cells (2 × 105) from donors (HLA-DR1+) vaccinated against TT were cultured in X-VIVO-20 and stimulated with mature autologous DCs (2 × 104) pulsed with the specific antigen (TT, 10 µg/mL).After several restimulations (3 to 4 times) every 7 days and expansion of the cell number by addition of IL-2 (10 U/mL), the peptide-specific proliferation was tested by means of specific and unspecific peptides. Prior to use in experiments, T cells were rested 7 to 8 days following the last restimulation. Three tyrosinase-specific CD8+ T-cell lines from 2 unrelated HLA-A2+ donors were generated and used for the experiments. MART-1-specific T-cell lines served as controls. Two TT-specific CD4+ T-cell lines from 2 unrelated HLA-DR1+ donors were generated and used for the experiments. Culture of human CD4+-antigen-specific T-cell clone HA1.7 The isolation of cloned T cells reactive with the influenza hemagglutinin antigen (HA peptide 307-319) has been reported in detail previously.28 The T-cell clone HA1.7 (kindly provided by Dr J. R. Lamb, St Mary's Hospital Medical School, London, United Kingdom) was cultured in RPMI 1640 (Gibco, Grand Islands, NY) supplemented with 100 U/mL penicillin (Gibco), 100 µg/mL streptomycin (Gibco), 2 mM glutamine (Gibco), and 10% screened human AB+ serum. Growing HA-reactive T cells were expanded with specific antigen (HA) in a proliferation-inducing dose (1 µg/mL) and HLA-DR1+ peripheral blood mononuclear cells every 7 days. After stimulation, the T-cell clone was fed with IL-2 (50 U/mL) every 3 to 4 days. Prior to their use in experiments, the T cells were rested 7 to 8 days following the last restimulation.Anergy assay and coculture experiments We prepared and cultured anergic and activated allogeneic CD4+ and CD8+ T cells, tyrosinase-specific CD8+ T cells, or the CD4+ T-cell clone HA1.7 as described above. T cells were cocultured during the first incubation at a density of 2 × 105 (allogeneic naive CD4+ and CD8+) or 1 × 105 (tyrosinase-specific CD8+ T cells, HA-specific CD4+ T-cell clone) with 1 × 104 DCs, pretreated with IL-10 (40 ng/mL), or left untreated to generate anergic or optimally stimulated activated T cells. At 36 hours later, T cells were separated by CD4+/CD8+ microbeads (Miltenyi) and rested for 2 days in culture medium containing 2 U/mL IL-2. Subsequently, T cells were restimulated with DCs generated from the same donor as was used for the first culture in experiments with allogeneic T cells and tyrosinase-specific T cells or with DCs generated from an HLA-DR1+ (CD4+ T-cell clone HA1.7) donor.To assess the suppressor activity of anergic T cells in the alloantigen-specific system, anergic CD4+ and CD8+ T cells (1 × 105) and syngeneic activated T cells (1 × 105) restimulated with 2 × 104 DCs (generated from the same donor as used in the primary culture) were used. In experiments with peptide-specific T cells (5 × 104), anergic CD4+ T cells of the clone HA1.7 or tyrosinase-specific CD8+ T cells were cocultured with (5 × 104) syngeneic activated T cells of the same specificity and restimulated with syngeneic mature DCs (5 × 103). In experiments analyzing the stimulatory effect of APCs on the suppressor activity of the anergic T cells, cocultured T cells were rescued after the first restimulation. Subsequently, these T cells were cultured without additional stimulation (APCs or IL-2) to remove anergic T cells from the culture as anergic T cells undergo rapid apoptosis under these conditions. Simultaneously, control experiments using anergic or activated T cells (stimulated with DCs or unstimulated) were performed to analyze the viability of the T cells. Viability was detected by trypan blue staining or mixed leukocyte reaction (MLR), indicating the complete death of anergic T cells after 2 to 3 days of culture, in contrast to activated control T cells. Afterward, the second restimulation experiments were performed. Proliferation was measured 48 to 72 hours later by thymidine incorporation. Tests were carried out in triplicate, and results were expressed as mean cpm ± SD. For blocking experiments, the following were used: antibodies to CTLA-4
(10 µg/mL); B7-1/B7-2 (Pharmingen) (10 µg/mL); IL-10 (R&D, Hamburg,
Germany) (10 µg/mL); and transforming growth factor (TGF)- Transwell experiments Transwell experiments were done in 24-well plates. Anergic alloantigen-specific 106 T cells or anergic peptide-specific (tyrosinase-specific) 2 × 105 T cells were stimulated with (105 or 2 × 104) mature DCs. Additionally, 106 control allogeneic or 2 × 105 activated peptide-specific T cells were either added directly to the cultures of anergic T cells or were placed in transwell chambers (0.4 µm) (Millicell) (Millipore, Bedford, MA) in the same well with (105 or 2 × 104) mature DCs (primed with the specific antigen). After 3 days of culture, activated T cells (2 × 105/well) were transferred to 96-well plates in triplicates. Proliferation was measured after an additional 16-hour pulse with 3H-Tdr by means of a liquid scintillation counter.Cytokine analysis For assessment of cytokine production, supernatants were collected 48 hours after restimulation of T cells with mature DCs and stored at 70°C. Amounts of IL-2, IL-4, IL-10, and IFN- were measured by enzyme-linked immunosorbent assay (ELISA) with the use of
commercially available antibodies and standards according to the
manufacturer`s protocols (Pharmingen).
Anergic T cells induced by IL-10-treated DCs suppress the activation of syngeneic alloantigen-specific T cells In previous studies, we demonstrated that IL-10-treated DCs induce an alloantigen-specific or peptide-specific anergy in cocultured CD4+ and CD8+ T cells. To assess suppressive effects of anergic T cells, we first analyzed the effect of alloantigen-specific anergic T cells on the proliferation of syngeneic activated T cells previously stimulated with mature DCs. First, 1 × 105 anergic CD4+ (Figure 1A) or CD8+ (Figure 1B) T cells were cocultured with the an equal number of syngeneic activated control T cells (1 × 105) of the same donor and restimulated with mature DCs (2 × 104) from the same DC donor that was used during the induction of anergy. Cocultures of anergic (1 × 105) or activated control T cells (1 × 105/2 × 105) with allogeneic mature DCs served as control. After 2 days, proliferation of activated control T cells cocultured with anergic T cells was markedly inhibited (Figure 1) compared with T lymphocytes stimulated only with mature DCs in the absence of syngeneic anergic T cells. As previously shown, anergic T cells stimulated with allogeneic DCs showed an impaired proliferation in contrast to T cells activated by allogeneic DCs in an MLR. To test whether these effects of anergic T cells in our system are alloantigen-specific, activated control T cells were generated from a second donor and used in the restimulation experiments. In contrast to the results described above, an unrestricted T-cell response was observed in these experiments independent of coculture with anergic or activated control T cells (Figure 1).
As shown in Figure 2, addition of various
numbers of anergic CD4+ T cells to cultures of activated
CD4+ T cells revealed that anergic T cells suppressed the
proliferation of syngeneic T cells in response to allogeneic mature DCs
in a dose-dependent manner. At a 1:1 ratio of anergic to activated T
cells, the proliferation of T cells is nearly reduced to the level of
proliferation of the anergic T lymphocytes alone (Figure 2). Similiar
results were obtained when naive syngeneic CD4+ T cells
were cocultured with anergic CD4+ T cells (data not shown).
These experiments demonstrate that anergic T cells induced by coculture with IL-10-treated DCs suppressed the activation of T cells in an alloantigen-specific manner and showed no unspecific bystander inhibition of the immune response. Antigen-specific suppression of cocultured T cells is induced by anergic T cells In our previous studies, we demonstrated that IL-10-treated DCs induce anergic T cells in peptide-specific models of T-cell activation. Thus, we assessed whether these anergic T cells are able to inhibit the activation of peptide-specific T cells. Anergic T cells (5 × 104) were incubated with syngeneic activated T cells (5 × 104) of the same specificity and stimulated with mature DCs of the same donor. In contrast to control experiments with activated T cells, inhibition of proliferation of cocultured syngeneic activated tyrosinase-specific CD8+ T cells (Figure 3A) or HA-specific CD4+ T cells (Figure 3B) was observed after coculture with anergic T cells.
To test the antigen/peptide specificity of this suppression, the anergic T cells were cocultured with syngeneic T cells specific for a second antigen (tyrosinase-specific T cells were cocultured with MART-1-specific T cells; HA-specific T cells, with TT-specific T cells). An unrestricted T-cell response was measured when syngeneic tyrosinase-specific anergic T cells and activated MART-1-specific CD8+ T cells (Figure 3A) or anergic HA-specific and TT-specific CD4+ T cells (Figure 3B) were cocultured in these experiments. These results suggest that the supression of anergic T cells in our system is not restricted to alloantigen-specific interactions but is also relevant for antigen-specific and peptide-specific interactions. No antigen-unspecific bystander inhibition is mediated by anergic T cells induced by IL-10-treated DCs. Cell-to-cell contact is required for the suppressive function of anergic T cells The observed immunosuppressive effect of anergic T cells could be mediated by surface molecules and/or by soluble mediators. To analyze the underlying mechanisms involved, transwell experiments were performed (Figure 4). Alloreactive anergic CD4+ T cells were either added directly to cocultures of activated control CD4+ T cells or placed in transwell chambers in the same well and activated with allogeneic mature DCs generated from the same donor used for induction of anergy. The semipermeable polycarbonate membrane allows the free exchange of soluble factors but excludes direct cell contact of the 2 cell populations. As shown in Figure 4, coculture experiments with syngeneic anergic and activated control T cells demonstrate a suppressed proliferation of cocultured control T cells. In contrast, separation of CD4+ T-cell populations in transwell chambers completely abrogated this immunosuppressive effect of anergic T cells. Alloreactive CD4+ T cells proliferated in the presence of allogeneic mature DCs, whereas control anergic T cells with low proliferative capacity showed only weak rates of expansion. In Figure 4, similiar results were shown in experiments with anergic tyrosinase-specific CD8+ T cells cocultured with syngeneic tyrosinase-specific CD8+ T cells.
Suppression requires T-cell stimulation by APCs Next, we assessed whether the presence of antigen-specific DCs is essential during the process of suppression. Coculture experiments of anergic alloantigen-specific CD4+ or tyrosinase-specific CD8+ T cells and activated control T cells were performed with DCs generated from the same donor used for anergy induction or without APCs. To exclude an inhibitory effect of the anergic T cells during the second restimulation, T cells were subsequently rescued and cultured without additional stimulation (DCs or IL-2) for 2 to 3 days to remove the anergic T cells as it has been demonstrated that anergic T cells undergo rapid apoptosis without further activation. To determine the time point of the initiation of the second restimulation, simultaneous experiments with isolated populations of control anergic or activated T cells (stimulated with DCs or without APCs) were performed, and the viability of the T cells was analyzed as described in "Materials and methods" (data not shown). The remaining T cells were restimulated with mature DCs, and the T-cell proliferation was measured after 2 to 3 days.No suppressor activity was observed if no dendritic cells (Figure
5) or DCs generated from an unrelated
second donor (data not shown) were used in the coculture of anergic and
activated control T cells. These results indicate that an
antigen-specific stimulation is necessary for the suppression of the
T-cell response, but do not distinguish between an effect of the APCs
on the induction of the regulatory properties of the anergic T cells
and an effect of the APCs on the activation of the target T cells to
become susceptible to the suppressor capacities of the anergic T cells.
Anergic T cells display increased surface and intracellular expression of the CTLA-4 molecule Activated T cells are characterized by the expression of typical surface molecules. To compare anergic CD4+ T lymphocytes induced by IL-10-treated DCs with activated control CD4+ T cells, kinetic studies of various surface molecules were performed.Figure 6A shows the results of FACS
analysis of anergic alloantigen-specific CD4+ T cells
obtained 48 hours after initiation of a restimulation experiment. After
restimulation with mature DCs as described in "Materials and
methods," anergic CD4+ T cells down-regulated activation
markers such as CD11a, CD25, CD28, and CD69 compared with activated T
lymphocytes previously activated by mature DCs in the primary culture.
No differences were observed in the expression of CD4, CD8, CD122 (beta
chain of the IL-2 receptor), CD95, or CD95L (data not shown). However, increased surface expression of the CTLA-4 molecule was observed (Figure 6A).
To address the role of the CTLA-4 molecule in the suppressor activity of anergic T cells, additional experiments were performed to analyze the surface and intracellular expression of the CTLA-4 molecule, which is known to be involved in down-regulation of T-cell function and in tolerance induction. Compared with activated CD4+ T cells stimulated with mature DCs, anergic CD4+ T cells are characterized by increased surface and intracellular expression of the CTLA-4 molecule after primary culture (day 5) and 24 and 48 hours after restimulation with mature DCs (Figure 6B). CTLA-4 is involved in the suppressor activity of anergic T cells The molecule CTLA-4 is known to be involved in the down-regulation of T-cell activation and tolerance induction. Since we detected an increased expression of the CTLA-4 molecule on anergic CD4+ T cells in our system, we wanted to investigate the role of the CTLA-4 molecule during immune suppression mediated by anergic T cells in experiments with neutralizing antibodies.Results demonstrated that blocking antibodies to the CTLA-4
molecule restored the T-cell activity up to 70% in experiments performed with anergic alloantigen-specific CD4+ T cells
(Figure 7).
Additionally, to test the importance of the costimulatory pathways mediated by B7-1/B7-2 molecules during the suppressor activity of anergic T cells, blocking mAbs to the costimulatory molecules B7-1 or B7-2 were used. As shown in Figure 7, blocking of the B7-2 pathway inhibited the suppressor activity of alloantigen-specific anergic CD4+ T cells. In contrast, no effect was observed when mAbs to the B7-1 molecule or control antibodies were used. Similar results were obtained for anergic peptide-specific T cells cocultured with activated T cells of the same specificity (data not shown). In control experiments, blocking antibodies to B7-1, B7-2, and CTLA-4 were added to control CD4+ T cells stimulated with mature DCs. As described previously, antibodies to B7-1/B7-2 blocked the stimulatory capacity of APCs, whereas anti-CTLA-4 mAb inhibited the negative regulation induced by activation of the CTLA-4 pathway (Figure 7).29,30 Soluble mediators are not involved in the suppressor activity of anergic T cells Immunosuppressive cytokines might be involved in the suppressor activity of anergic T cells. Therefore, we assessed the cytokine pattern of T cells after restimulation with mature DCs by ELISA. Compared with activated control CD4+ and CD8+ T cells, anergic CD4+ or CD8+ T cells showed a markedly reduced secretion of the cytokines IL-2 and IFN-, but
little or no production of IL-4 or IL-10, as described before (Table
1).16 After coculture of
anergic and syngeneic tyrosinase-specific CD8+ T cells, a
similar cytokine pattern was measured (Table 1). These data indicate
blocking of TH1/TC1 cytokine production without a shift to a TH2/TC2 pattern in anergic and
cocultured T cells (Table 1).
The inhibitory effect of anergic T cells on the proliferation of
syngeneic T cells of the same specificity might be a result of unknown
soluble inhibitory factors produced by anergic T cells, which were not
detectable by the conventional ELISAs used. To test this hypothesis,
transfer experiments with supernatants of anergic alloantigen-specific
CD4+ or CD8+ T cells were performed. These
supernatants were added to syngeneic (alloantigen-specific) control
CD4+ or CD8+ T cells additionally stimulated
with mature DCs generated from the same donor used for anergy induction
(Figure 8). Addition of supernatants
harvested from anergic T cells did not mimic the suppressor activity of
anergic T cells, indicating that soluble mediators such as cytokines
cannot mediate the suppressor function of anergic T cells (Figure 8).
Further experiments showed that high doses of IL-2, but not blocking
antibodies to IL-10 or TGF-
In our study, we demonstrate that human anergic T cells induced by IL-10-treated DCs display suppressor activity in an antigen-specific manner. In both the allogeneic and a peptide-specific system, CD4+ and CD8+ T cells inhibited the proliferation and activity of cocultured T cells. This suppressor activity required cell-to-cell contact and antigen-pulsed DCs and was not transferred by soluble mediators. The induction of antigen-specific tolerance is critical for the prevention of autoimmunity and maintenance of immune homeostasis. The ability of the immune system to distinguish between self and nonself and between innocuous and harmful antigens is controlled by mechanisms of central and peripheral tolerance.1-5 Several mechanisms, including induction of clonal deletion, cell death, and anergy, are well characterized.2-5 In addition, active inhibition by regulatory or suppressor T cells is also crucial for maintaining tolerance in the periphery.31 At present, the term "regulatory" T cells is used to describe a variety of T-cell subsets with regulatory properties based on the expression of surface molecules, cytokine production, and functional assays.31 One of the best-characterized populations of murine regulatory CD4+ T cells is defined by a constitutive expression of the alpha chain of the IL-2 receptor (CD25).32 These cells arise from the thymus of naive mice, and their function and activation are thought to be essential for the maintenance for self-tolerance and control of autoimmunity.33 They compose 5% to 10% of the peripheral CD4+ T cells in mice and suppress immune responses in vivo and in vitro via non-antigen-specific mechanisms.32,34 Recently, it was demonstrated that regulatory CD4+ CD25+ T cells with similiar properties also exist in the human system.35-39 A subset of regulatory CD4+ cells was developed by addition
of IL-10 to primary murine T-cell culture and was termed Tr
(regulatory)-1 cells.40 Tr1 cells are distinct from
TH1/TH2 cells in that they produce high levels
of IL-10, moderate amounts of TGF- A role for DCs in the induction of peripheral tolerance has been
proposed by several studies.25,26,44,45 Most of these studies support the notion that the maturation state of DCs and/or subtype of DCs are fundamental in the induction of peripheral tolerance.46,47 Recently, it was shown that immature human DCs may control peripheral tolerance by inducing the differentation of
human nonproliferating Tr-like (regulatorylike) cells with regulatory
properties in vitro and in vivo.47,48 The CD4+
T cells induced by immature DCs in vitro and CD8+ T cells
induced in vivo appear to share key properties with Tr cells in that
they both produce high amounts of IL-10 and suppress the activation of
cocultured T cells in an antigen-nonspecific fashion.48,49
The suppressor activity requires cell-to-cell contact, but
immunsuppressive cytokines such as IL-10 and TGF- In contrast to regulatory Tr or Tr-like cells induced by immature DCs
or CD4+/CD25+ T cells, anergic T cells induced
by IL-10-treated human DCs suppress the activity of cocultured T cells
in an antigen-specific mechanism as demonstrated in allogeneic and
peptide-specific systems. Additionally, anergic suppressor T cells show
no production of imunosuppressive cytokines such as IL-10 or TGF- In further contrast to CD4+/CD25+ T cells in the murine and human system, the anergic T cells in our study express reduced surface levels of CD25 as demonstrated by FACS analysis, and depletion of the CD4+/CD25+ T-cell subpopulation did not inhibit the suppressor activity of the anergic T cells (unpublished data, 2001). In our hands, the suppressor T cells induced by coculture with
IL-10-treated DCs display high surface and extracellular expression of
the CTLA-4 molecule. Evidence exists that CTLA-4 can act as a negative
regulator of T-cell activation.49 CTLA-4 deficiency or
blockade induces or exacerbates autoimmunity, enhances tumor immunity,
or prevents induction of immunologic tolerance.50-52 In
agreement with these results, blocking of the CTLA-4 signaling on
anergic T cells induced by IL-10-treated DCs inhibits the suppressor activity of the T cells, pointing toward an important role of the
CTLA-4 pathway for the suppressor function of anergic T cells in our
system. Recent studies have shown that regulatory T cells stimulated
via CTLA-4 predominantly secrete TGF- Additionally, IL-10-treated DCs can also induce anergic CD8+ suppressor T cells. Compared with CD4+ T cells, anergy among CD8+ T cells is less well characterized, although anergic CD8+ T cells have been induced in vivo and in vitro.53-55 Furthermore, similiar to CD4+ Tr cells, CD8+ Tr cells can be isolated in vitro after multiple stimulations and are known to suppress antigen-specific responses by down-regulation of CD86 expression on APCs.56 Furthermore, CD8+ suppressor cells, which regulate the immune responses via immunosuppressive cytokines (IL-4, IL-5, or IL-10), were identified in vivo in the murine model of low zone tolerance or in patients suffering from leprosy.57,58 Anergic CD8+ T cells induced by IL-10-treated DCs inhibit the proliferation of cocultured CD8+ T cell in an antigen-specific manner without any effect on cocultured DCs as observed by analyzing the accessory capacity and the expression of surface molecules on DCs after coculture with anergic T cells (unpublished data). Furthermore, similar to anergic CD4+ T cells, anergic CD8+ T cells with suppressor activity do not release immunosuppressive cytokines. The concept that anergic CD4+ T cells can exert regulatory effects as suppressor cells was demonstrated in vivo and in vitro.25,26,59-62 More importantly, to the best of our knowledge, this study is the first report to show that human anergic CD8+ T cells have suppressor properties. Our observation that IL-10-treated DCs induce anergic CD4+/CD8+ T cells with antigen-specific suppressor activity opens new therapeutic perpectives for the use of DCs in vivo. Induction of anergic T cells might be exploited therapeutically for suppression of cellular immune responses in allergic or autoimmune diseases with identified (auto-) antigens.
The authors thank Dr H. Jonuleit, Dr E. von Stebut, and Dr T. Tüting for critical reading of the manuscript.
Submitted July 10, 2001; accepted November 20, 2001.
Supported by a grant from the German Research Foundation (SFB548/B6 and A6).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Kerstin Steinbrink, Department of Dermatology, University of Mainz, Langenbeckstr 1, D-55131 Mainz, Germany; e-mail: steinbrink{at}hautklinik.klinik.uni-mainz.de.
1.
Ramsdell F, Fowlkes BJ.
Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance.
Science.
1990;248:1342-1348 2. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381:434-438[CrossRef][Medline] [Order article via Infotrieve].
3.
Rocha B, Grandien A, Freitas AA.
Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance.
J Exp Med.
1995;181:993-1003 4. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 1990;63:1249-1256[CrossRef][Medline] [Order article via Infotrieve].
5.
Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL.
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis.
Science.
1994;265:1237-1240 6. Webb SR, Hutchinson J, Hayden K, Sprent J. Expansion/deletion of mature T cells exposed to endogeneous superantigens in vivo. J Immunol. 1994;152:586-596[Abstract].
7.
Takahashi T, Tagami T, Yamazaki S, et al.
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
J Exp Med.
2000;192:303-310
8.
Schwartz RH.
Models of T cell anergy: is there a common molecular mechanism?
J Exp Med.
1996;184:1-8
9.
Jenkins MK, Schwartz RH.
Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo.
J Exp Med.
1987;165:302-319 10. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T cell anergy by altered T cell-receptor ligand on live antigen-presenting cells. Nature. 1993;363:156-159[CrossRef][Medline] [Order article via Infotrieve].
11.
Rellahan BL, Jones LA, Kruisbeck AM, Fry AM, Matis LA.
In vivo induction of anergy in peripheral V beta 8+ T cells by staphyloccocal enterotoxin B.
J Exp Med.
1991;172:1091-1100
12.
Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM.
Partial T cell signaling: altered phospho 13. Li W, Whaley CD, Mondino A, Mueller DL. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science. 1996;271:1272-1276[Abstract]. 14. Fields PE, Gajewski TF, Fitch FW. Blocked RAS activation in anergic CD4+ T cells. Science. 1996;271:1276-1278[Abstract].
15.
DeSilva D, Feeser WS, Tancula EJ, Scherle PA.
Anergic T cells are defective in both jun NH2terminal-kinase and mitogen-activated protein kinase signaling pathways.
J Exp Med.
1996;183:2017-2023
16.
Lombardi G, Sidhu S, Batchelor R, Lechler R.
Anergic T cells as suppressor cells in vitro.
Science.
1994;264:1587-1589 17. Chai JG, Bartok I, Chandler P, et al. Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol. 1999;29:686-692[CrossRef][Medline] [Order article via Infotrieve]. 18. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252[CrossRef][Medline] [Order article via Infotrieve]. 19. de Waal Malefyt RW, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol. 1992;4:314-320[CrossRef][Medline] [Order article via Infotrieve]. 20. Chang CH, Furue M, Tamaki K. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol. 1995;25:394-398[Medline] [Order article via Infotrieve].
21.
Koch F, Stanzl U, Jennewein P, et al.
High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.
J Exp Med.
1996;184:741-746 22. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol. 1997;27:1229-1235[Medline] [Order article via Infotrieve].
23.
Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA.
Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells.
J Immunol.
1999;162:3865-3872 24. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. J Immunol. 1993;151:2390-2398[Abstract]. 25. Steinbrink K, Wölfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997;159:4772-4780[Abstract].
26.
Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk AH.
Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells.
Blood.
1999;93:1634-1642 27. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142[Medline] [Order article via Infotrieve]. 28. Lamb JR, Eckels DD, Lake P, Woody JN, Green N. Human T cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature. 1982;300:66-63[CrossRef][Medline] [Order article via Infotrieve].
29.
Carreno BM, Bennett F, Chau TA, et al.
CLTA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
J Immunol.
2000;165:1352-1356 30. Anerson DE, Bieganowska KD, Bar-Or A, et al. Paradoxical inhibition of T cell function in response to CTLA-4 blockade: heterogenity within the human T cell population. Nat Med. 2000;2:211-214. 31. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol. 2000;18:423-449[CrossRef][Medline] [Order article via Infotrieve].
32.
Suri-Payer E, Amar AZ, Thornton AM, Shevach EM.
CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.
J Immunol.
1998;160:1212-1218
33.
Itoh M, Takahashi T, Sakaguchi N, et al.
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.
J Immunol.
1999;162:5317-5326
34.
Thornton AM, Shevach EM.
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen non-specific.
J Immunol.
2000;164:183-190 35. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol. 2001;31:1122-1131[CrossRef][Medline] [Order article via Infotrieve].
36.
Jonuleit J, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH.
Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood.
J Exp Med.
2001;193:1227-1238
37.
Levings MK, Sangregorio R, Roncarolo M-G.
Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.
J Exp Med.
2001;193:1295-1302
38.
Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G.
Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood.
J Exp Med.
2001;193:1303-1310
39.
Taylor PA, Noelle RJ, Blazar BR.
CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.
J Exp Med.
2001;193:1311-1318 40. Groux H, O'Garra A, Bigler M, et al. A CD4+ T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature. 1997;389:737-742[CrossRef][Medline] [Order article via Infotrieve].
41.
Cottrez F, Hurst SD, Coffman RL, Groux H.
T regulatory cells 1 inhibit a Th2-specific response in vivo.
J Immunol.
2000;165:4848-4853
42.
Thornton AM, Shevach EM.
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.
J Exp Med.
1998;188:287-296 43. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol. 1999;73:153-264[Medline] [Order article via Infotrieve]. 44. Fairchild PJ, Waldmann H. Dendritic cells and prospects for transplantation tolerance. Curr Opin Immunol. 2000;12:528-535[CrossRef][Medline] [Order article via Infotrieve].
45.
Steinman RM, Turley S, Mellman I, Inaba K.
The induction of tolerance by dendritic cells that have captured apoptotic cells.
J Exp Med.
2000;191:411-416 46. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol. 2000;12:114-121[CrossRef][Medline] [Order article via Infotrieve].
47.
Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH.
Induction of interleukin 10-producing, non-proliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.
J Exp Med.
2000;192:1213-1222
48.
Dhopdapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N.
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.
J Exp Med.
2001;193:233-238 49. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413[CrossRef][Medline] [Order article via Infotrieve].
50.
Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA.
CTLA-4: a negative regulator of autoimmune disease.
J Exp Med.
1996;184:783-788 51. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997;6:411-417[CrossRef][Medline] [Order article via Infotrieve]. 52. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-1736[Abstract]. 53. Dillon SR, MacKay VL, Fink PJ. A functionally compromised intermediate in extrathymic CD8+ T cell deletion. Immunity. 1995;3:321-333[CrossRef][Medline] [Order article via Infotrieve].
54.
Dubois PM, Pihlgren M, Tomkowiak M, Van Mechelen M, Marvel J.
Tolerant CD8 T cells induced by multiple injections of peptide antigen show impaired TCR signaling and altered proliferative responses in vitro and in vivo.
J Immunol.
1998;161:5260-5267
55.
Blish CA, Dillon SR, Farr AG, Fink PJ.
Anergic CD8+ T cells can persist and function in vivo.
J Immunol.
1999;163:155-164
56.
Li J, Liu Z, Jiang S, Cortesini R, Lederman S, Suciu-Foca S.
T suppressor lymphocytes inhibit NK-
57.
Steinbrink K, Macher E, Sorg C.
Low zone tolerance to contact allergens in mice: a functional role for CD8+ T helper type 2 cells.
J Exp Med.
1996;183:759-768
58.
Salgame P, Abrams JS, Clayberger C, et al.
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones.
Science.
1991;254:279-282 59. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science. 1994;264:1587-1589.
60.
Miller C, Ragheb JA, Schwartz RH.
Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo.
J Exp Med.
1999;190:53-64 61. Chai JG, Bartok I, Chandler P, et al. Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol. 1999;29:686-692. 62. Jordan MS, Riley MP, von Boehmer H, Caton AJ. Anergy and suppression regulate CD4+ T cell responses to a self peptide. Eur J Immunol. 2000;30:136-144[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Chamorro, J. J. Garcia-Vallejo, W. W. J. Unger, R. J. Fernandes, S. C. M. Bruijns, S. Laban, B. O. Roep, B. A. 't Hart, and Y. van Kooyk TLR Triggering on Tolerogenic Dendritic Cells Results in TLR2 Up-Regulation and a Reduced Proinflammatory Immune Program J. Immunol., September 1, 2009; 183(5): 2984 - 2994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zhao, C. Falk, W. Osen, M. Kato, D. Schadendorf, and V. Umansky Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma Clin. Cancer Res., July 1, 2009; 15(13): 4382 - 4390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. M. Bamboat, J. A. Stableford, G. Plitas, B. M. Burt, H. M. Nguyen, A. P. Welles, M. Gonen, J. W. Young, and R. P. DeMatteo Human Liver Dendritic Cells Promote T Cell Hyporesponsiveness J. Immunol., February 15, 2009; 182(4): 1901 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Goto, T. Arigami, M. Kitago, S. L. Nguyen, N. Narita, S. Ferrone, D. L. Morton, R. F. Irie, and D. S.B. Hoon Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors Mol. Cancer Ther., November 1, 2008; 7(11): 3642 - 3653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lagaraine, R. Lemoine, C. Baron, H. Nivet, F. Velge-Roussel, and Y. Lebranchu Induction of human CD4+ regulatory T cells by mycophenolic acid-treated dendritic cells J. Leukoc. Biol., October 1, 2008; 84(4): 1057 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bjorck, A. Beilhack, E. I. Herman, R. S. Negrin, and E. G. Engleman Plasmacytoid Dendritic Cells Take Up Opsonized Antigen Leading to CD4+ and CD8+ T Cell Activation In Vivo J. Immunol., September 15, 2008; 181(6): 3811 - 3817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Salazar, O Aravena, P Abello, A Escobar, J Contreras-Levicoy, N Rojas-Colonelli, D Catalan, A Aguirre, R Zuniga, B Pesce, et al. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells Ann Rheum Dis, September 1, 2008; 67(9): 1235 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Agaugue, E. Marcenaro, B. Ferranti, L. Moretta, and A. Moretta Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells Blood, September 1, 2008; 112(5): 1776 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mathew, K. L. Bauer, A. Fischoeder, N. Bhardwaj, and S. J. Oliver The Anergic State in Sarcoidosis Is Associated with Diminished Dendritic Cell Function J. Immunol., July 1, 2008; 181(1): 746 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Poncini, C. D. A. Soto, E. Batalla, M. E. Solana, and S. M. Gonzalez Cappa Trypanosoma cruzi Induces Regulatory Dendritic Cells In Vitro Infect. Immun., June 1, 2008; 76(6): 2633 - 2641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamaura, C. Hotta, M. Nakazawa, L. Van Kaer, and M. Minami Human invariant V{alpha}24+ natural killer T cells acquire regulatory functions by interacting with IL-10-treated dendritic cells Blood, April 15, 2008; 111(8): 4254 - 4263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Cools, P. Ponsaerts, V. F. I. Van Tendeloo, and Z. N. Berneman Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells J. Leukoc. Biol., December 1, 2007; 82(6): 1365 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne The cross-talk between dendritic and regulatory T cells: good or evil? J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsumura, T. Kobayashi, K. Ichiyama, R. Yoshida, M. Hashimoto, T. Takimoto, K. Tanaka, T. Chinen, T. Shichita, T. Wyss-Coray, et al. Selective Expansion of Foxp3-Positive Regulatory T Cells and Immunosuppression by Suppressors of Cytokine Signaling 3-Deficient Dendritic Cells J. Immunol., August 15, 2007; 179(4): 2170 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hamdi, V. Godot, M.-C. Maillot, M. V. Prejean, N. Cohen, R. Krzysiek, F. M. Lemoine, W. Zou, and D. Emilie Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper Blood, July 1, 2007; 110(1): 211 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Suciu-Foca, N. Feirt, Q.-Y. Zhang, G. Vlad, Z. Liu, H. Lin, C.-C. Chang, E. K. Ho, A. I. Colovai, H. Kaufman, et al. Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients J. Immunol., June 1, 2007; 178(11): 7432 - 7441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Demirkiran, B. M. Bosma, A. Kok, C. C. Baan, H. J. Metselaar, J. N. M. IJzermans, H. W. Tilanus, J. Kwekkeboom, and L. J. W. van der Laan Allosuppressive Donor CD4+CD25+ Regulatory T Cells Detach from the Graft and Circulate in Recipients after Liver Transplantation J. Immunol., May 15, 2007; 178(10): 6066 - 6072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Adler, S. Kubsch, E. Graulich, S. Ludwig, J. Knop, and K. Steinbrink Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells Blood, May 15, 2007; 109(10): 4351 - 4359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bros, F. Jahrling, A. Renzing, N. Wiechmann, N.-A. Dang, A. Sutter, R. Ross, J. Knop, S. Sudowe, and A. B. Reske-Kunz A newly established murine immature dendritic cell line can be differentiated into a mature state, but exerts tolerogenic function upon maturation in the presence of glucocorticoid Blood, May 1, 2007; 109(9): 3820 - 3829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Qian, H. An, Y. Yu, S. Liu, and X. Cao TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation Blood, April 15, 2007; 109(8): 3308 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Lan, Z. Wang, G. Raimondi, W. Wu, B. L. Colvin, A. De Creus, and A. W. Thomson "Alternatively Activated" Dendritic Cells Preferentially Secrete IL-10, Expand Foxp3+CD4+ T Cells, and Induce Long-Term Organ Allograft Survival in Combination with CTLA4-Ig J. Immunol., November 1, 2006; 177(9): 5868 - 5877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Qian, X. Jiang, H. An, Y. Yu, Z. Guo, S. Liu, H. Xu, and X. Cao TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation Blood, October 1, 2006; 108(7): 2307 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. von Bergwelt-Baildon, A. Popov, T. Saric, J. Chemnitz, S. Classen, M. S. Stoffel, F. Fiore, U. Roth, M. Beyer, S. Debey, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition Blood, July 1, 2006; 108(1): 228 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Han, S. Wang, Y. Fan, J. Yang, L. Jiao, H. Qiu, and X. Yang Chlamydia Infection Induces ICOS Ligand-Expressing and IL-10-Producing Dendritic Cells That Can Inhibit Airway Inflammation and Mucus Overproduction Elicited by Allergen Challenge in BALB/c Mice J. Immunol., May 1, 2006; 176(9): 5232 - 5239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Barchet, J. D. Price, M. Cella, M. Colonna, S. K. MacMillan, J. P. Cobb, P. A. Thompson, K. M. Murphy, J. P. Atkinson, and C. Kemper Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation Blood, February 15, 2006; 107(4): 1497 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Elrefaei, B. Barugahare, F. Ssali, P. Mugyenyi, and H. Cao HIV-Specific IL-10-Positive CD8+ T Cells Are Increased in Advanced Disease and Are Associated with Decreased HIV-Specific Cytolysis J. Immunol., January 15, 2006; 176(2): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Guriec, C. Daniel, K. Le Ster, E. Hardy, and C. Berthou Cytokine-regulated expression and inhibitory function of Fc{gamma}RIIB1 and -B2 receptors in human dendritic cells J. Leukoc. Biol., January 1, 2006; 79(1): 59 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mocellin, F. M. Marincola, and H. A. Young Interleukin-10 and the immune response against cancer: a counterpoint J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, H. Huang, J. Yuan, D. Sun, W.-S. Hou, J. Gordon, and J. Xiang CD4-8- Dendritic Cells Prime CD4+ T Regulatory 1 Cells to Suppress Antitumor Immunity J. Immunol., September 1, 2005; 175(5): 2931 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Baratelli, Y. Lin, L. Zhu, S.-C. Yang, N. Heuze-Vourc'h, G. Zeng, K. Reckamp, M. Dohadwala, S. Sharma, and S. M. Dubinett Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells J. Immunol., August 1, 2005; 175(3): 1483 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Boettler, H. C. Spangenberg, C. Neumann-Haefelin, E. Panther, S. Urbani, C. Ferrari, H. E. Blum, F. von Weizsacker, and R. Thimme T Cells with a CD4+CD25+ Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8+ T Cells during Chronic Hepatitis C Virus Infection J. Virol., June 15, 2005; 79(12): 7860 - 7867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vlad, R. Cortesini, and N. Suciu-Foca License to Heal: Bidirectional Interaction of Antigen-Specific Regulatory T Cells and Tolerogenic APC J. Immunol., May 15, 2005; 174(10): 5907 - 5914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gregori, P. Mangia, R. Bacchetta, E. Tresoldi, F. Kolbinger, C. Traversari, J. M. Carballido, J. E. de Vries, U. Korthauer, and M.-G. Roncarolo An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells J. Exp. Med., April 18, 2005; 201(8): 1293 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Smith, T. Patterson, and M. E. Pauza Transgenic Ly-49A Inhibits Antigen-Driven T Cell Activation and Delays Diabetes J. Immunol., April 1, 2005; 174(7): 3897 - 3905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cong, A. Konrad, N. Iqbal, R. D. Hatton, C. T. Weaver, and C. O. Elson Generation of Antigen-Specific, Foxp3-Expressing CD4+ Regulatory T Cells by Inhibition of APC Proteosome Function J. Immunol., March 1, 2005; 174(5): 2787 - 2795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brustoski, U. Moller, M. Kramer, A. Petelski, S. Brenner, D. R. Palmer, M. Bongartz, P. G. Kremsner, A. J. F. Luty, and U. Krzych IFN-{gamma} and IL-10 Mediate Parasite-Specific Immune Responses of Cord Blood Cells Induced by Pregnancy-Associated Plasmodium falciparum Malaria J. Immunol., February 1, 2005; 174(3): 1738 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Levings, S. Gregori, E. Tresoldi, S. Cazzaniga, C. Bonini, and M. G. Roncarolo Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells Blood, February 1, 2005; 105(3): 1162 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lee, H. Torisu-Itakara, A. J. Cochran, A. Kadison, Y. Huynh, D. L. Morton, and R. Essner Quantitative Analysis of Melanoma-Induced Cytokine-Mediated Immunosuppression in Melanoma Sentinel Nodes Clin. Cancer Res., January 1, 2005; 11(1): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Bella, S. Nicola, I. Timofeeva, M. L. Villa, A. Santoro, and A. C. Berardi Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? Blood, December 15, 2004; 104(13): 4020 - 4028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Isolauri, S Rautava, and M Kalliomaki Food allergy in irritable bowel syndrome: new facts and old fallacies Gut, October 1, 2004; 53(10): 1391 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, K. Doffek, S. L. Sugg, and J. Shilyansky Phosphatidylserine Regulates the Maturation of Human Dendritic Cells J. Immunol., September 1, 2004; 173(5): 2985 - 2994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Raftery, D. Wieland, S. Gronewald, A. A. Kraus, T. Giese, and G. Schonrich Shaping Phenotype, Function, and Survival of Dendritic Cells by Cytomegalovirus-Encoded IL-10 J. Immunol., September 1, 2004; 173(5): 3383 - 3391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Avigan, B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atkins, J. Mier, D. McDermott, T. Smith, et al. Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses Clin. Cancer Res., July 15, 2004; 10(14): 4699 - 4708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vigouroux, E. Yvon, E. Biagi, and M. K. Brenner Antigen-induced regulatory T cells Blood, July 1, 2004; 104(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. F. H. M. Boonman, G. J. D. van Mierlo, M. F. Fransen, K. L. M. C. Franken, R. Offringa, C. J. M. Melief, M. J. Jager, and R. E. M. Toes Intraocular Tumor Antigen Drains Specifically to Submandibular Lymph Nodes, Resulting in an Abortive Cytotoxic T Cell Reaction J. Immunol., February 1, 2004; 172(3): 1567 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nefedova, M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove, and D. Gabrilovich Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer J. Immunol., January 1, 2004; 172(1): 464 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mahnke, Y. Qian, J. Knop, and A. H. Enk Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells Blood, June 15, 2003; 101(12): 4862 - 4869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Senju, S. Hirata, H. Matsuyoshi, M. Masuda, Y. Uemura, K. Araki, K.-i. Yamamura, and Y. Nishimura Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells Blood, May 1, 2003; 101(9): 3501 - 3508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guillot, S. Menoret, C. Guillonneau, C. Braudeau, M. G. Castro, P. Lowenstein, and I. Anegon Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig Blood, April 15, 2003; 101(8): 3325 - 3333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Woltman and C. van Kooten Functional modulation of dendritic cells to suppress adaptive immune responses J. Leukoc. Biol., April 1, 2003; 73(4): 428 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Steel and T. B. Nutman CTLA-4 in Filarial Infections: Implications for a Role in Diminished T Cell Reactivity J. Immunol., February 15, 2003; 170(4): 1930 - 1938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Brown, D. M. Dorfman, F.-R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield, and G. J. Freeman Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production J. Immunol., February 1, 2003; 170(3): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Muller, E. Shagdarsuren, J.-K. Park, R. Dechend, E. Mervaala, F. Hampich, A. Fiebeler, X. Ju, P. Finckenberg, J. Theuer, et al. Immunosuppressive Treatment Protects Against Angiotensin II-Induced Renal Damage Am. J. Pathol., November 1, 2002; 161(5): 1679 - 1693. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
and lack of zap70 recruitment in APL-induced T cell anergy.
Cell.
1994;79:913-922
B-mediated transcription of CD86 gene in APC.
J Immunol.
1999;163:6386-6392